Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nolato ABFRA:NBF +1.47%75 EV-to-EBIT is 14.84 as of Aug. 21, 2026, which is 10% below its 10-year median of 16.48. GuruFocus rates FRA:NBF with a GF Score™ of 75/100 and a GF Value™ of €4.64 (Fairly Valued). The stock has 2 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Nolato AB ranks better than 61.52% on this metric.
The historical rank and industry rank for Nolato AB's EV-to-EBIT or its related term are showing as below:
FRA:NBF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.97 Med: 16.48 Max: 24.09
Current: 15.01
During the past 13 years, the highest EV-to-EBIT of Nolato AB was 24.09. The lowest was 8.97. And the median was 16.48.
FRA:NBF's EV-to-EBIT is ranked better than 61.52% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 18.87
vs FRA:NBF: 15.01
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nolato AB's Enterprise Value for the quarter that ended in Jun. 2026 was €1,084.7 Mil.
Nolato AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB EV-to-EBIT Related Terms
Nolato AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nolato AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nolato AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nolato AB's EV-to-EBIT falls into.
Nolato AB's current Enterprise Value is €1,339.2 Mil.
Nolato AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a EV-to-EBIT of 14.84 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nolato AB and its competitors. This is 10% below median its historical median of 16.48. Over the past decade, Nolato AB's EV-to-EBIT has ranged from 8.97 to 24.09. According to the industry distribution chart, Nolato AB ranks #182 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 38.5%.
Is Nolato AB's EV-to-EBIT too high?
Nolato AB's current EV-to-EBIT of 14.84 is 10% below median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 8.97 to a high of 24.09. The Medical Devices & Instruments industry median EV-to-EBIT is 18.87. Nolato AB's value of 14.84 is 21.4% below this industry median. Based on the distribution chart, Nolato AB ranks #182 out of 473 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nolato AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #182 out of 473 companies for EV-to-EBIT. This puts Nolato AB in the upper half of its industry. The industry median EV-to-EBIT is 18.87. Nolato AB's value of 14.84 is 21.4% below this benchmark. Historically, Nolato AB's own EV-to-EBIT has ranged from 8.97 to 24.09 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 18.87, Nolato AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current EV-to-EBIT of 14.84 is 21.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current EV-to-EBIT is 14.84, which is 10% below median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.64, compared to a current price of €4.49 — trading 3.2% below its estimated fair value. The current EV-to-EBIT is 14.84, which is 10% below median its 10-year median of 16.48 and 21.4% below the Medical Devices & Instruments industry median of 18.87. Nolato AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current EV-to-EBIT is 14.84 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.49 is trading 3.2% below its estimated GF Value™ of €4.64.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
EV-to-EBIT: 14.84 (10% below median its 10-year median of 16.48)
GF Value™: €4.64 vs. price of €4.49 (3.2% below fair value)
Industry Position: 21.4% below the Medical Devices & Instruments median (#182 of 473)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
75GF Score
Get the complete analysis for FRA:NBF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
